VUNO is a South Korea-based medical AI company that develops artificial intelligence solutions for clinical diagnosis and decision support. Specializing in radiology, pathology, and cardiology, VUNO creates cutting-edge software that assists medical professionals by rapidly analyzing medical images and clinical data.
Founded in 2014, VUNO stands for “View, Understand, Navigate, Observe,” which reflects its mission to equip healthcare professionals with AI tools that improve speed, accuracy, and consistency in patient diagnosis. By applying deep learning to medical imaging and other health data, VUNO accelerates workflows and supports early detection of critical conditions.
VUNO’s AI solutions have been approved by multiple regulatory bodies, including the Korean Ministry of Food and Drug Safety (MFDS), and some products have achieved CE certification, enabling international adoption.
Features
VUNO’s product suite spans across radiology, pathology, cardiology, and vital sign analysis. One of its flagship products is VUNO Med–LungCT AI, which automatically detects and classifies lung nodules from chest CT scans. It uses deep learning to identify potential malignancies and helps radiologists prioritize findings.
VUNO Med–BoneAge is another core product that estimates bone age from hand X-rays in pediatric patients, helping diagnose growth disorders with high precision and speed. The model is trained on large-scale clinical datasets and can produce consistent, reproducible results in seconds.
In cardiology, VUNO Med–DeepECG analyzes electrocardiogram (ECG) waveforms to detect abnormal patterns, aiding in the early detection of cardiac conditions. The system can identify atrial fibrillation, tachycardia, and other anomalies, offering real-time analysis for clinicians.
For pathology, VUNO Med–Path AS is an AI-based software for analyzing prostate biopsy slides. It assists pathologists in identifying cancerous areas, grading tumors, and improving diagnostic consistency.
Another innovative feature is VUNO Med–Fundus AI, which screens retinal fundus images for signs of diabetic retinopathy and other eye diseases. The tool is intended for primary care settings to support early detection in patients who may not have access to specialized ophthalmology care.
All VUNO products are built to integrate with hospital PACS (Picture Archiving and Communication Systems) and electronic medical records, enabling real-time AI assistance in routine clinical workflows.
How It Works
VUNO’s AI models are built on deep learning frameworks trained on large, annotated medical datasets. These models are developed through partnerships with leading hospitals and academic institutions to ensure clinical relevance and accuracy.
In practice, a clinician uploads a medical image such as a CT scan, X-ray, ECG, or histopathology slide into the VUNO software. The AI system analyzes the input, detects abnormalities, classifies findings, and returns results—often within seconds. The output includes visual highlights of areas of interest, confidence scores, and diagnostic suggestions.
The system is designed to support—not replace—clinicians, offering second-opinion assistance, reducing oversight, and accelerating decision-making. VUNO’s tools also log results and support auditing, providing traceability for clinical reviews and regulatory compliance.
VUNO’s software can be deployed on-premise or via cloud integration, depending on the infrastructure of the healthcare provider. It is compatible with global standards such as DICOM for imaging and HL7 for health data exchange.
Use Cases
Radiologists use VUNO Med–LungCT AI and VUNO Med–Chest X-ray to rapidly triage critical cases, such as detecting lung cancer or pneumonia, especially in busy hospital environments where speed is critical.
Pediatric endocrinologists rely on VUNO Med–BoneAge to assess skeletal maturity in children with growth disorders, helping guide treatment plans without requiring manual bone atlas comparisons.
Cardiologists and emergency physicians use DeepECG to detect cardiac abnormalities from ECG readings in real time, allowing earlier intervention for conditions such as arrhythmia or heart failure.
Pathologists integrate VUNO Med–Path AS into digital pathology workflows to standardize prostate cancer diagnoses, reducing inter-observer variability and enhancing workflow efficiency.
In ophthalmology and primary care settings, VUNO Med–Fundus AI enables screening for retinal diseases, expanding access to preventive care in underserved or rural communities.
Pricing
VUNO does not publish standard pricing on its website. As a B2B solution provider, VUNO offers custom pricing based on deployment scale, products used, and integration requirements.
Healthcare organizations interested in using VUNO solutions are encouraged to contact the company for a personalized quote and deployment consultation. VUNO offers flexible licensing models, including subscription-based access, volume-based pricing, and enterprise contracts for hospitals and diagnostic labs.
Strengths
VUNO’s key strength is its broad portfolio of AI diagnostic tools spanning multiple specialties. Rather than focusing on a single domain, VUNO supports radiology, pathology, cardiology, and general diagnostics, making it a comprehensive solution provider.
The company’s strong clinical validation and regulatory approvals across multiple countries make it a trusted choice for healthcare institutions seeking reliable AI solutions.
VUNO’s solutions are designed to be easily integrated into existing hospital systems, ensuring smooth adoption and minimal disruption to workflows.
Speed is another advantage. VUNO’s tools generate diagnostic results in seconds, helping clinicians make faster decisions and reduce reporting bottlenecks.
The platform’s visual output and explainability features provide transparency into AI decisions, aiding clinician trust and regulatory compliance.
Drawbacks
One limitation is that VUNO’s primary market is South Korea and select international regions, which may limit accessibility for healthcare providers in regions where regulatory clearance has not yet been obtained.
Another consideration is that AI-generated outputs are dependent on image quality. Poor-quality scans or inconsistent input data can affect the accuracy of results.
Although VUNO provides valuable clinical decision support, it still requires clinician oversight, and integration into workflows may require initial training and change management to ensure staff adoption.
For smaller clinics or practices, the cost and infrastructure requirements for AI deployment may be a barrier compared to larger health systems.
Comparison with Other Tools
VUNO competes with global medical AI companies like Aidoc, Zebra Medical Vision, Lunit, and Arterys. Compared to Aidoc and Zebra Medical Vision, which focus heavily on emergency radiology triage, VUNO offers a broader set of tools including ECG and pathology AI.
Lunit, also based in South Korea, focuses on chest X-ray and mammography AI. While Lunit and VUNO share strengths in imaging AI, VUNO distinguishes itself with products in ECG and pathology, which expands its clinical footprint.
Compared to Arterys, which is cloud-native and heavily reliant on MRI data, VUNO offers on-premise flexibility and more diversity in imaging modalities such as X-rays, CT, and histology.
VUNO’s advantage lies in its multi-specialty AI suite and rapid result generation, which support both outpatient clinics and hospital networks.
Customer Reviews and Testimonials
While individual user reviews are not prominently listed on the VUNO website, the company has shared multiple clinical validation studies and use-case collaborations with leading Korean hospitals such as Seoul National University Hospital and Asan Medical Center.
Physicians working with VUNO have noted improvements in diagnostic consistency, faster triage, and reduced manual workload. Medical centers using VUNO solutions have reported increased accuracy in detecting early-stage disease, particularly in high-volume radiology departments.
VUNO has received multiple awards and recognition in the healthtech industry, including regulatory certifications, investor confidence, and partnerships with major global imaging companies.
Conclusion
VUNO is an innovative AI company at the forefront of medical diagnostics, offering a suite of clinically validated tools that enhance diagnostic accuracy and speed across radiology, cardiology, and pathology.
By combining deep learning with real-world clinical data, VUNO delivers actionable insights that help clinicians detect diseases earlier, reduce diagnostic errors, and optimize workflows. Its scalable architecture and modular design make it suitable for hospitals, imaging centers, and research institutions seeking to integrate AI into routine care.
With continued global expansion, ongoing regulatory approvals, and a growing portfolio of solutions, VUNO is well-positioned to shape the future of AI-powered healthcare.
